Logo-ps

Submitted: 29 Nov 2025
Revision: 11 Apr 2026
Accepted: 15 Apr 2026
ePublished: 19 Aug 2026
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Pharm Sci. 2026;32(4): 623-631.
doi: 10.34172/ps.43560
  Abstract View: 281
  PDF Download: 105

Original Article

Development of a Probe Based on UiO-66 MOF for Determination of Paclitaxel in Urine Samples

Reza Moharami 1,2 ORCID logo, Zahra Karimzadeh 3,4, Yosra Vaez-Gharamaleki 5, Jafar Soleymani 6, Elaheh Rahimpour 6* ORCID logo, Abolghasem Jouyban 6,7

1 Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
2 Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3 Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran
4 Engineered Biomaterials Research Center, Khazar University, Baku, Azerbaijan
5 Hematology & Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
6 Pharmaceutical Analysis Research Center, Pharmaceutical Sciences Institute, Tabriz University of Medical Sciences, Tabriz, Iran
7 Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
*Corresponding Author: Elaheh Rahimpour, Email: rahimpour_e@yahoo.com

Abstract

Introduction: Accurate and precise determination of paclitaxel is crucial due to its widespread use as a frontline treatment for various types of cancer, as well as its implementation in various drug delivery strategies. The objective of this study was to validate a facile fluorescent probe utilizing the UiO-66 metal-organic framework (MOF) to quantify paclitaxel in urine samples.

Results: In the presence of paclitaxel and proportional to its concentration, the fluorescence intensity of UiO-66 MOF gradually decreased due to the formation a non-fluorescent complex during the interaction of paclitaxel and UiO-66 MOF. This platform demonstrated a linear response within the paclitaxel concentration range of 0.01 to 1.5 μg.mL−1, with a detection limit of 0.007 μg.mL−1. The UiO-66 MOF based probe’s relative standard deviation for five replicated measurements of paclitaxel were 1.4% and 2.6% (n=5) for intra-day and inter-day, respectively.

Conclusion: The results indicated that this robust and low-cost fluorescent probe was a promising platform for analyzing paclitaxel in clinical applications.


First Name
Last Name
Email Address
Comments
Security code


Abstract View: 282

Your browser does not support the canvas element.

PDF Download: 105

Your browser does not support the canvas element.